12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BKT-140: Phase IIa started

This quarter, BioLineRx will begin an open-label, dose-escalation, U.S. and Israeli Phase IIa trial to evaluate BL-8040 in up to 50 adults with relapsed or refractory AML. Biokine...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >